

**CONCLUSION**

A Three month extension of time is attached. The Commissioner is authorized to debit our Deposit Account No. 502855, accordingly. If any questions or issues remain, the resolution of which the Examiner feels would be advanced by a conference with Applicant, the Examiner is invited to contact Applicant's attorney at the number noted below.

Respectfully submitted,

By: 

Theodore Allen  
Registration No. 41,578  
Cytoc Corporation  
85 Swanson Road  
Boxborough, MA 01719

USPTO Customer No. 0000 38732

**Version with Markings to Show Changes Made**

**In the Claims:**

1. A method for identifying a patient having an increased risk for developing breast precancer or breast cancer, said method comprising the following steps:

- (a) introducing a ductal access tool into a breast duct, said access tool comprising [at least one] elongated lumen;
- (b) introducing a fluid into the breast duct through said [at least one] elongated lumen;
- (c) retrieving a ductal fluid sample from within the breast duct through said [at least one] lumen, said ductal fluid being free of any ductal fluid from another duct of the breast; and
- (d) detecting a viral agent in the ductal fluid sample.

12. A method of treating a patient at risk for or having a breast precancer or breast cancer, said method comprising the following steps:

- (a) introducing a ductal access tool into a breast duct, said access tool comprising [at least one] elongated lumen;
- (b) introducing a fluid into the breast duct through said [at least one] elongated lumen;
- (c) retrieving a ductal fluid sample from within the breast duct through said [at least one] lumen;

- (d) detecting a viral agent in the retrieved ductal fluid sample from the breast duct; and
- (e) delivering to the patient a composition comprising an antiviral agent specific for the detected viral agent.